Psychologists in Solvang, CA Accepting Medicare
6 Psychologists found. Showing 1 - 6
 Dr. Charles Michael Lepkowsky, PH.D. Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 1143 Deer Trail Ln, Solvang, CA 93463 Phone: 805-688-1229 Fax: 805-686-9382 |
 Dr. Corinne Jo Curtis, PH.D. Psychologist - Clinical Child & Adolescent Medicare: Not Enrolled in Medicare Practice Location: 1610 Oak St Ste 203, Solvang, CA 93463 Phone: 805-570-0288 |
Dr. Christina L Pouquette, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1199 Deer Hill Dr, Solvang, CA 93463 Phone: 805-252-5144 |
Dr. Stephanie M Holthaus, PH.D. Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 540 Alisal Rd, Suite 3, Solvang, CA 93463 Phone: 805-245-2916 |
Dr. Jean Clemens, PH.D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 540 Alisal Rd, Suite 3, Solvang, CA 93463 Phone: 805-350-1631 Fax: 805-688-4485 |
Christopher Rydman Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 1693 Mission Dr Ste 207, Solvang, CA 93463 Phone: 213-926-2110 |
News Archive
Individuals who naturally lack CCR5 receptor have resistant to HIV
UCLA AIDS Institute researchers successfully removed CCR5 - a cell receptor to which HIV-1 binds for infection but which the human body does not need - from human cells. Individuals who naturally lack the CCR5 receptor have been found to be essentially resistant to HIV.
Discovery about fatty tissue that burns fat
In an article now being published in the leading American journal PNAS, a research team led by Barbara Cannon and Jan Nedergaard at the Wenner-Gren Institute, Stockholm University in Sweden, together with British and American scientists, have managed to show for the first time that the cells that become the so-called brown or white fat tissue already know from the very beginning what sort of fat tissue they will be.
Genzyme updates on Cerezyme supply plus 2009 financials
Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company's 2009 financial results. The company's Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.
Researchers identify new kidney cancer subtypes and clues to better diagnosis, treatment
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
Proteostasis Therapeutics enters into exclusive license agreement with New York University
Proteostasis Therapeutics announced today that it has entered into an exclusive license agreement with New York University for intellectual property related to discoveries from the laboratory of David Ron, M.D., Professor of Medicine and Julius Raynes Professor of Cell Biology at NYU Langone Medical Center's Skirball Institute of Biomolecular Medicine.
› Verified 7 days ago
Counselors
Dentists
Psychologists
Pharmacists
Occupational Therapists
Clinical Social Workers